RT Journal Article
SR Electronic
T1 Transcriptional patterns of coexpression across autism risk genes converge on established and novel signatures of neurodevelopment
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.28.22271620
DO 10.1101/2022.02.28.22271620
A1 Calwing Liao
A1 Mariana Moyses-Oliveira
A1 Celine EF De Esch
A1 Riya Bhavsar
A1 Xander Nuttle
A1 Aiqun Li
A1 Alex Yu
A1 Nicholas D. Burt
A1 Serkan Erdin
A1 Jack M. Fu
A1 Minghui Wang
A1 Theodore Morley
A1 Lide Han
A1 CommonMind Consortium
A1 Patrick A. Dion
A1 Guy A. Rouleau
A1 Bin Zhang
A1 Kristen J. Brennand
A1 Michael E. Talkowski
A1 Douglas M. Ruderfer
YR 2022
UL http://medrxiv.org/content/early/2022/03/01/2022.02.28.22271620.abstract
AB Autism spectrum disorder (ASD) is a highly heritable neurodevelopmental disorder characterized by deficits in social interactions and communication. Protein function altering variants in many genes have been shown to contribute to ASD risk; however, understanding the biological convergence across so many genes has been difficult. Here, we demonstrate that coexpression patterns from human post-mortem brain samples (N=993) are significantly correlated with the transcriptional consequences of CRISPR perturbations (gene editing, interference and activation) of 15 neurodevelopmental genes in neuronal cell models. We find that across 70 ASD risk genes, there is significant tissue-specific transcriptional convergence that implicates synaptic pathways. We further show that the degree of convergence is significantly correlated with the level of association to ASD from sequencing studies (rho = −0.14, P = 4.75×10−63) as well as differential expression from transcription studies in post-mortem ASD brains (rho = −0.22, P = 3.62×10−41). After removing genes with minimal evidence of association with ASD, the remaining positively convergent genes are intolerant to mutation, have shorter coding lengths and are enriched for genes with suggestive evidence of contribution to ASD. These results indicate that leveraging convergent coexpression can identify novel ASD risk genes that are more likely to be underpowered and therefore missed by current large-scale sequencing studies. This work ultimately provides a simple approach to functionally proxy CRISPR perturbation, demonstrates significant context-specific transcriptional convergence among known ASD risk genes, and proposes several novel ASD risk gene candidates.Competing Interest StatementThe authors have declared no competing interest.Funding StatementC.L. was supported by a Vanier Graduate Scholarship from the Canadian Institutes of Health Research (CIHR). M.M.O. and J.M.F. were supported by Autism Speaks Foundation Postdoctoral Fellowships (#11815 and #11852, respectively). X.N. was supported by F32MH115614) and K99MH121577. G.A.R. was supported by a CIHR Foundation Scheme grant (#332971). This work was also supported by R01MH123155 (DMR, KJB, MET), R01HD096326 (MET), R01NS093200 (MET), R01MH111776 (DMR), and the Simons Foundation for Autism Research (#573206 to MET). Data were generated as part of the CommonMind Consortium supported by funding from Takeda Pharmaceuticals Company Limited, F. Hoffman-La Roche Ltd and NIH grants R01MH085542, R01MH093725, P50MH066392, P50MH080405, R01MH097276, RO1-MH- 075916, P50M096891, P50MH084053S1, R37MH057881, AG02219, AG05138, MH06692, R01MH110921, R01MH109677, R01MH109897, U01MH103392, U01MH116442, project ZIC MH002903 and contract HHSN271201300031C through IRP NIMH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research abided by ethical regulations and was approved by the Vanderbilt University Medical Center Review Board (IRB: 220287).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNearly all data are publicly available and sources are described in the manuscript. The few that are not can be made available on request.